Medical Health & Life Science Research News

Report explores Frontier Pharma: Women’s health-an expanding therapy area, with endometriosis therapies prominent among the first-in-class pipeline

Medical Market Research

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause.

Summary

Many of these disorders are highly prevalent among the female population.

Despite this, the women’s health market is relatively small. This reflects diagnostic barriers and high levels of non-treatment for women’s health disorders, as well as high levels of generalization and relatively limited innovation within recent decades.

Consequently, there is strong rationale for continued R&D investment in women’s health therapeutics due to high levels of unmet need across many indications.

This report assesses first-in-class innovation across the women’s health therapy area, with a particular focus on three key indications: endometriosis, polycystic ovarian syndrome (PCOS) and cervical intraepithelial neoplasia (CIN).

Request a sample of this report @ orbisresearch.com/contacts/request-sample/2097727 .

Scope

- Many women’s health disorders are highly prevalent. How do epidemiology trends vary for endometriosis, PCOS and CIN?

- Innovation within women’s health has been relatively limited over recent decades. What are the most prominent unmet needs across this therapy area?

- There are 261 pipeline programs in active development for women’s health. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?

- Although the first-in-class pipeline is relatively modest in size it is considerably diverse with eight distinct molecular target classes represented. Which first-in-class targets have been identified as most promising for women’s health conditions?

- Over 200 licensing deals relating to women’s health have been completed since 2006. Do women’s health products typically attract high deal values? Which first-in-class products have prior deal involvement?

Browse the complete report @ orbisresearch.com/reports/index/fr…in-class-pipeline .

Reasons to access

- Understand the current clinical and commercial landscape. This includes a comprehensive study of symptoms, epidemiology, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment options.

- Visualize the composition of the women’s health market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.

- Analyze the women’s health pipeline and stratify by stage of development, molecule type and molecular target.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential.

Promising first-in-class targets have been reviewed in greater detail.

- Recognize commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals, and identifying women’s health therapies that have not yet been involved in deals and may offer potential investment opportunities.

Access this report @ orbisresearch.com/contact/purchase/2097727 .

Some Points from Table of Content:

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Executive Summary 6

2.1 Expanding Pipeline Has Potential to Address Unmet Needs of Large Prevalence Population 6

2.2 First-in-Class Innovation Concentrated Across Endometriosis, Polycystic Ovarian Syndrome and Cervical Intraepithelial Neoplasia 6

2.3 Despite High Licensing Deal Activity, Most First-in-Class Products Have No Prior Deal Involvement 6

3 The Case for Innovation 7

3.1 Growing Opportunities for Biologic Products 8

3.2 Diversification of Molecular Targets 8

3.3 Innovative First-in-Class Product Developments Remain Attractive 8

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9

3.5 Sustained Innovation in Women’s Health 9

3.6 GBI Research Report Guidance 10

4 Clinical and Commercial Landscape 11

4.1 Therapy Area Overview 11

4.2 Disease Overview and Symptoms 11

4.2.1 Endometriosis 11

4.2.2 Polycystic Ovarian Syndrome 12

4.2.3 Cervical Intraepithelial Neoplasia 12

4.3 Diagnosis 13

4.3.1 Endometriosis 13

4.3.2 Polycystic Ovarian Syndrome 13

4.3.3 Cervical Intraepithelial Neoplasia 14

4.4 Epidemiology and Etiology 14

4.4.1 Endometriosis 14

4.4.2 Polycystic Ovarian Syndrome 15

4.4.3 Cervical Intraepithelial Neoplasia 16

4.5 Pathophysiology 16

4.5.1 Endometriosis 16

4.5.2 Polycystic Ovarian Syndrome 17

4.5.3 Cervical Intraepithelial Neoplasia 18

4.6 Co-morbidities and Complications 18

4.6.1 Endometriosis 18

4.6.2 Polycystic Ovarian Syndrome 19

4.6.3 Cervical Intraepithelial Neoplasia 19

4.7 Treatment 19

4.7.1 Treatment Options 19

4.7.2 Treatment Algorithms 23

4.8 Overview of Marketed Products within Women’s Health 24

News From

Orbis Research - Rendering Conscientious ResearchOrbis Research
Category: Market Research Publishers and RetailersCompany about: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from the leading publishers and authors across the gl obe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their need, and we produce the perfect requi ...
This email address is being protected from spambots. You need JavaScript enabled to view it.